5-Amino-1MQ

Clinical Disclaimer: 5-Amino-1MQ is NOT FDA-approved for any indication. As of April 2026, NO registered human clinical trials have been completed or published. Evidence for efficacy and safety is entirely preclinical (cell culture and animal models). Clinical use in humans is investigational. This monograph is for qualified healthcare professionals and does not constitute prescribing guidance.

1. Introduction and Overview

5-Amino-1-methylquinolinium (5-Amino-1MQ, or 5A-1MQ) is a selective, membrane-permeable small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is strictly not a peptide — it is a quinolinium salt-structured small molecule — but has entered the peptide-prescribing space because it is frequently combined with NAD+ precursor protocols and metabolic/longevity peptide stacks in compounded clinical practice. This monograph addresses 5-Amino-1MQ on the same schema as peptide monographs for consistency, while making its chemical class and entirely-preclinical evidence base explicit.

The scientific interest in NNMT inhibition is substantial: NNMT is a metabolic enzyme whose expression is elevated in obesity, type 2 diabetes, non-alcoholic fatty liver disease, and several cancers. Inhibiting NNMT raises intracellular NAD+ via an indirect mechanism and — in rodent models of obesity — produces weight loss, adipocyte size reduction, and improved metabolic parameters without reduction in food intake. Those findings prompted the development of 5-Amino-1MQ as the prototype selective, orally bioavailable NNMT inhibitor, and prompted clinical interest that has outpaced the actual published human clinical evidence.

2. Chemistry and Biochemistry

2.1 Structure

5-Amino-1MQ is 5-amino-1-methylquinolinium — a methylated quinoline derivative bearing a 5-amino substituent. Unlike peptides, it is a rigid small-molecule heteroaromatic structure with the molecular formula C10H11N2+ (cation; supplied typically as the iodide salt C10H11IN2, MW approximately 286.11 g/mol) or as alternative salt forms. It is designed to be membrane-permeable, cell-active, and orally bioavailable — distinguishing it from many earlier NNMT-inhibitor research tools that lacked the physicochemical properties needed for in vivo use.

2.2 NNMT biochemistry

Nicotinamide N-methyltransferase (EC 2.1.1.1, gene NNMT) catalyzes transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). NNMT is most highly expressed in liver, white adipose tissue, and skeletal muscle. Its activity has two metabolic consequences:

• NAD+ pool reduction — NAM is the principal precursor for NAD+ resynthesis via the salvage pathway; NNMT methylates NAM and removes it from the recyclable pool.
• Methyl-group consumption — each reaction consumes one SAM molecule, contributing to SAH accumulation and potentially altering methylation-pathway homeostasis.

Knockdown of NNMT in preclinical models (Kraus et al. Nature 2014) protects mice from high-fat-diet-induced obesity, demonstrating that NNMT activity is rate-limiting for diet-induced adipose expansion and providing the target-validation basis for 5-Amino-1MQ development.

3. Mechanism of Action

3.1 Direct enzymatic inhibition

5-Amino-1MQ is a selective NNMT inhibitor — it binds the enzyme active site and reduces its catalytic activity in cell-based and animal models. Selectivity over related methyltransferases has been demonstrated in biochemical screens. The molecule is membrane-permeable, allowing it to reach intracellular NNMT in adipocytes, hepatocytes, and other target tissues.

3.2 Downstream metabolic consequences

NNMT inhibition with 5-Amino-1MQ produces three interconnected effects in preclinical models:

• NAD+ pool elevation — more nicotinamide is preserved for salvage-pathway NAD+ resynthesis; intracellular NAD+ rises.
• Reduced 1-MNA — 1-MNA is both an NNMT product and has independent signaling roles; its reduction is a marker of NNMT inhibition and contributes to altered lipid handling.
• Restored sirtuin activity — higher NAD+ supports SIRT1 and SIRT3 activity, with downstream effects on mitochondrial biogenesis, fatty-acid oxidation, and adipocyte differentiation.

3.3 Adipocyte and body-composition effects in mice

In preclinical models (Neelakantan et al. Biochem Pharmacol 2018, and subsequent publications), 5-Amino-1MQ treatment:

• Reduced white adipose tissue mass without affecting food intake.
• Decreased mean adipocyte size.
• Reduced body weight in high-fat-diet-fed mice.
• Improved metabolic markers (insulin sensitivity, glucose tolerance) in some models.
• Produced no observable adverse effects at efficacious doses (in the rodent studies published).

3.4 Muscle and sarcopenia research

Neelakantan et al. (Biochem Pharmacol 2019) reported that small-molecule NNMT inhibition activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle in rodent models. This extends the potential therapeutic scope beyond obesity into age-related sarcopenia and muscle-quality research, though similarly without human trial validation.

4. Clinical Evidence — Important Caveat

As of April 2026, NO registered human clinical trials of 5-Amino-1MQ have been completed or published. ClinicalTrials.gov and the EU Clinical Trials Register contain no completed trials of this molecule. This is a critical distinction from many peptides in the compounded-practice space: strong preclinical evidence does not substitute for human clinical data, and prescribers should not infer efficacy in humans from the mouse adipose-tissue findings.

Compounded clinical use exists — some 503A pharmacies prepare 5-Amino-1MQ as oral capsules, and some clinicians prescribe it for weight loss, body-composition support, or as part of metabolic/longevity protocols. This use is empirical and off-label; the dosing regimens in compounded practice are derived from rodent pharmacokinetic extrapolation rather than human pharmacokinetic or safety studies.

5. Prescribing Considerations

5.1 Dosing

No FDA-established or human-trial-validated dose exists. Compounded-practice oral dosing has been reported in the 50–150 mg once-daily range, with cycle durations of 4–12 weeks. These values should be considered empirical extrapolation from animal data, not evidence-based prescribing guidance. Parenteral routes are not commonly used in clinical practice.

5.2 Practical pearls

• Framing matters: when discussing 5-Amino-1MQ with a patient, make the preclinical-only evidence base explicit. The preclinical data is encouraging; the human data does not exist.
• This is a small molecule, not a peptide. Compounded quality control — identity, purity by HPLC, lot-specific Certificate of Analysis — applies as rigorously as with peptides.
• Co-administration with NAD+ precursors (NR, NMN) has theoretical additive effects on NAD+ pool elevation but has not been tested in controlled human settings.
• Methyl-group homeostasis is a concern: NNMT consumes methyl groups, so inhibition may shift methylation-pathway flux. Monitor homocysteine on chronic use and consider methyl-donor support (methylated B vitamins) in patients with elevated baseline homocysteine.
• Avoid in any patient with active malignancy — NNMT biology in cancer is complex, with NNMT overexpression in multiple tumor types and unresolved questions about how inhibition affects tumor metabolism.
• Document informed consent explicitly reflecting the preclinical-only evidence base and investigational nature.

6. Safety and Monitoring

6.1 Adverse effects

Preclinical safety studies in rodents showed no observable adverse effects at efficacious doses, but this cannot be extrapolated to long-term human use. Anecdotal compounded-practice reports include mild GI upset, headache, fatigue, and muscle cramps. The rare-event profile in humans is entirely uncharacterized.

6.2 Serious safety considerations

• No completed human safety studies exist; long-term safety is unknown.
• Theoretical concerns about chronic methylation-pathway disruption are not excluded.
• Effects on cancer biology are unresolved — NNMT is upregulated in many tumors and its inhibition in those contexts could be beneficial or harmful; precaution in any patient with a history of or active malignancy.
• Pregnancy and lactation: contraindicated due to absence of human safety data and unstudied reproductive toxicity.
• Hepatic and renal impairment: no human pharmacokinetic data — use with extreme caution or avoid.

6.3 Monitoring

• Weight, waist circumference, and body composition at baseline and every 4–12 weeks.
• CBC, CMP (including liver and renal function) at baseline and every 3 months.
• HbA1c and fasting glucose at baseline and every 3–6 months.
• Lipid panel at baseline and every 6 months.
• Homocysteine at baseline and every 6 months — NNMT inhibition affects methylation-pathway flux.
• Thyroid function (TSH) at baseline and every 6–12 months.
• Vital signs and symptom diary at each visit.
• Documented informed consent reviewed and re-discussed with each renewal.

7. Regulatory Status

5-Amino-1MQ is not FDA-approved for any indication. It is not a scheduled or controlled substance. Compounded availability exists through some 503A pharmacies, typically as oral capsules. Regulatory status for any compounded preparation should be verified per jurisdiction — state boards of pharmacy and the FDA periodically update positions on novel compounded substances. Given the absence of human trials, 5-Amino-1MQ occupies a regulatory and clinical gray zone similar to several investigational peptides in the space.

8. Summary

NNMT is a scientifically compelling metabolic target. 5-Amino-1MQ is a well-designed, selective, membrane-permeable small-molecule inhibitor with robust preclinical support for its anti-obesity and metabolic effects in rodent models. The translational step to human clinical efficacy and safety has not been taken — no registered human clinical trials have been completed or published. For prescribers, this means that any use is genuinely investigational, that patient framing and informed consent must reflect the preclinical-only evidence base honestly, and that monitoring should be conservative with particular attention to methylation-pathway markers. The biology is interesting; the clinical reality is early-stage.

Bottom line: strong preclinical target validation and mouse adipose-tissue data; ZERO completed human clinical trials as of April 2026. Preclinical-only evidence, small molecule not peptide; document consent accordingly.